Steve Qi

Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome

Diane M. Hargrove, Sudarkodi Alagarsamy, Glenn Croston et al. · Journal of Pharmacology and Experimental Therapeutics · 2020 · 56 citations · Full text

Pharmacological Characterization of FE 202158, a Novel, Potent, Selective, and Short-Acting Peptidic Vasopressin V1a Receptor Full Agonist for the Treatment of Vasodilatory Hypotension

Régent Laporte, Arash Kohan, Joshua Heitzmann et al. · Journal of Pharmacology and Experimental Therapeutics · 2011 · 38 citations

Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance

Kazimierz Wiśniewski, Javier Sueiras-Diaz, Guangcheng Jiang et al. · Journal of Medicinal Chemistry · 2016 · 36 citations · Full text

Analogues 69, Molecular Pharmacology, Low Systemic Clearance +15

New, Potent, and Selective Peptidic Oxytocin Receptor Agonists

Kazimierz Wiśniewski, Sudarkodi Alagarsamy, Robert Galyean et al. · Journal of Medicinal Chemistry · 2014 · 34 citations · Full text

Functional Selectivity, Medicine, Physiology +13

Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor*

Sebastian Rehberg, Perenlei Enkhbaatar, Janina Rehberg et al. · Critical Care Medicine · 2012 · 16 citations · Full text